**FOI Ref: 6325**

**Category(ies): Clinical - Drugs**

**Subject: Metastatic/Breast Cancer Patients**

**Date Received: 01/04/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:  * Abemaciclib (Verzenios) + aromatase inhibitor \* * Abemaciclib (Verzenios) + Fulvestrant (Faslodex) * Alpelisib (Piqray) + Fulvestrant (Faslodex) * Atezolizumab (Tecentriq)\*\* * Bevacizumab (Avastin) * Eribulin (Halaven) * Everolimus (Afinitor) + Exemestane * Fulvestrant (Faslodex) as a single agent * Gemcitabine + paclitaxel * Herceptin (Trastuzumab) + paclitaxel * Herceptin (Trastuzumab) as a single agent * Lapatinib (Tyverb) * Neratinib (Nerlynx) * Olaparib (Lynparza) * Palbociclib (Ibrance) + aromatase inhibitor\* * Palbociclib (Ibrance) + Fulvestrant (Faslodex) * Pertuzumab (Perjeta) + trastuzumab + docetaxel * Ribociclib (Kisqali) + aromatase inhibitor\* * Ribociclib (Kisqali) + Fulvestrant (Faslodex) * Talazoparib (Talzenna) * Trastuzumab emtansine (Kadcyla) * Other active systemic anti-cancer therapy \*\*   \*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole  \*\*eg. docetaxel, vinorelbine or capecitabine as a single agent | Systemic Anti-Cancer Therapy for Breast cancer patients is delivered by Weston Park; therefore, we are unable to answer this request.  The request would need to go to Sheffield Teaching Hospitals who can be contacted via email at [sth.foi@nhs.net](mailto:sth.foi@nhs.net) |
| Q2. For the above patients, how many of these received their first ever dose for each product line? |  |